5/22/2024
Anokion Announces New Clinical Data from ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
The Celiac Disease Foundation is pleased to share important research and clinical trial news from Anokion, a biotechnology company evaluating a treatment for celiac disease. Using our iQualifyCeliac screening platform, the Foundation has supported patient enrollment through recruitment and eligibility screening for three of Anokion’s past and current trials: ACeD (Phase 1), ACeD-it (Phase 1b/2),…
Continue Reading